OUR TEAM IS MADE OF WORLD-RENOWNED SCIENTISTS AND EXPERIENCED BUSINESS LEADERS
CEO Dr. Bruno Jactel
Bruno Jactel, Co-founder and CEO, is a seasoned executive with expertise in biotechnology, commercialization, and global market strategy. As former Chief Marketing and Innovation Officer at Sanofi-Merial, he led high-impact initiatives across a $3 billion division with 5,000 employees. With a Doctorate in Veterinary Medicine (DVM) from the University of Toulouse and both an MBA and an M.S. in Agricultural Economics from Sorbonne University, Bruno brings a powerful combination of scientific expertise and business leadership. His track record in scaling biotech solutions and navigating complex regulatory landscapes positions the company for strong industry leadership.
CSO Dr. Loic Deblais
Loic Deblais is expert in food safety and diagnostic innovation, with deep experience developing cutting-edge detection technologies for the agricultural and pharmaceutical industries. His expertise spans pathogen detection, microbiology, and biotechnology-driven food safety solutions. Loic holds a Ph.D. in Food Safety and Microbiology from Ohio State University and has been instrumental in advancing next-generation diagnostic tools that enhance food security and public health.
CCO Brian McFarlane
Brian McFarlane is a food safety industry veteran with extensive leadership experience in global protein production and risk mitigation. As former VP/Head of Food Safety at JBS Foods, the world’s largest protein company, he led high-impact food safety initiatives across a vast supply chain, ensuring regulatory compliance and industry-leading standards. With a Master’s in Meat Science from Kansas State University, Brian brings deep expertise in pathogen control, quality assurance, and large-scale food safety strategy, positioning the company at the forefront of innovation in contamination detection and prevention.
Advisors
Sam Jactel
Sam Jactel, co-founder, is a seasoned leader in diagnostics with a proven track record in biotech innovation and commercialization. He played a pivotal role in shaping product strategy for Ginkgo Bioworks’ COVID-response program, driving large-scale deployment of diagnostic solutions. With experience as a venture capital investor, strategy consultant, and published clinical researcher in chronic and infectious diseases, he brings a unique blend of scientific expertise and business acumen to the company. Sam holds an MBA from Northwestern University’s Kellogg School of Management.